Cargando…
Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response
In oncology trials, overall survival (OS) is considered the most reliable and preferred endpoint to evaluate the benefit of drug treatment. Other relevant variables are also collected from patients for a given drug and its indication, and it is important to characterize the dynamic effects and links...
Autores principales: | Bender, Brendan C, Schindler, Emilie, Friberg, Lena E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Science Inc
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294077/ https://www.ncbi.nlm.nih.gov/pubmed/24134068 http://dx.doi.org/10.1111/bcp.12258 |
Ejemplares similares
-
Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022) -
The pharmacokinetic–pharmacodynamic modelling framework as a tool to predict drug resistance evolution
por: Witzany, Christopher, et al.
Publicado: (2023) -
Using Network Biology to Bridge Pharmacokinetics and Pharmacodynamics in Oncology
por: Kirouac, D C, et al.
Publicado: (2013) -
An Approach for Identifiability of Population Pharmacokinetic–Pharmacodynamic Models
por: Shivva, V, et al.
Publicado: (2013) -
Precision Cardio-Oncology: Use of Mechanistic Pharmacokinetic and Pharmacodynamic Modeling to Predict Cardiotoxicities of Anti-Cancer Drugs
por: Wen, Hai-ni, et al.
Publicado: (2022)